Zoetis Reports Strong Q4 Earnings, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 04 2026
0mins
Should l Buy ZTS?
Source: Benzinga
Zoetis shares fell 5.01% and hit a 5-day low amid broader market gains, with the Nasdaq-100 up 0.26% and the S&P 500 up 0.34%.
The company reported Q4 net income of $603 million, or $1.37 per share, which was slightly below analyst expectations of $1.40. Revenue rose 3% to $2.38 billion, surpassing market expectations. Despite the earnings miss, Zoetis provided a positive outlook for 2026, anticipating net income between $2.825 billion and $2.875 billion, which reflects confidence in future growth.
The mixed earnings report may have led to the stock's decline, as investors reacted to the slight earnings miss despite the revenue beat and optimistic guidance. This indicates a potential sector rotation as investors reassess their positions in light of the earnings results.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 122.720
Low
130.00
Averages
154.20
High
200.00
Current: 122.720
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of Investment Prospects in Healthcare Stocks
- Animal Health Leader: Zoetis has faced challenges over the past two years, including increased competition and scrutiny over drug side effects; however, its strong market position and the potential market for untreated dogs make it attractive for long-term investors, with expectations to continue launching new products to meet rising pet spending.
- New Drug Development Potential: BioNTech has underperformed in the coronavirus vaccine market, but its impressive pipeline with over 25 clinical trials in oncology, particularly the promising BNT327 developed with Bristol Myers Squibb, could set new standards of care across multiple indications, with significant clinical and regulatory progress expected over the next five years.
- Gene Editing Risks: Intellia Therapeutics' lonvo-z and nex-z are undergoing phase 3 studies but face uncertainty; despite the FDA lifting the hold on clinical trials, the high costs and complexities of gene editing treatments make steady revenue generation unlikely in the coming years, presenting substantial investment risks.
- Dividend Appeal: Zoetis has increased its dividends by 458% over the past decade, making it a top choice for income-seeking investors, reflecting its long-term investment value in the animal health market despite facing short-term challenges.
See More
Latest Rating Changes on Wall Street
- Apple's Positive Outlook: Wells Fargo reiterates Apple (AAPL) as overweight, anticipating better-than-expected iPhone demand and continued double-digit growth in services ahead of its earnings report, with a price target of $300.
- SolarEdge Downgraded: Goldman Sachs downgrades SolarEdge (SEDG) from neutral to sell, citing elevated expectations and challenging valuation as key factors behind the downgrade.
- Meta's Advertising Growth: Deutsche Bank maintains a buy rating on Meta (META), highlighting that its investments in AI are yielding increasing returns for advertisers, which supports accelerated advertising revenue growth.
- Autodesk Positioned Well: Jefferies initiates coverage on Autodesk (ADSK) with a buy rating, noting its strong positioning in agentic AI and solid fundamentals, presenting an attractive risk/reward profile at current levels.
See More
Zoetis Earnings Outlook Shows Optimism Ahead
- Stock Performance: Zoetis (ZTS) fell 1.78% to $117.86 in the latest trading session, underperforming the S&P 500's 0.11% decline, indicating market caution regarding its short-term outlook.
- Earnings Expectations: The company is set to report an EPS of $1.61 on May 7, 2026, representing an 8.78% increase year-over-year, with revenue projected at $2.31 billion, reflecting a 4.02% growth, showcasing its sustained growth potential in the animal health sector.
- Analyst Ratings: Currently holding a Zacks Rank of #3 (Hold), Zoetis has seen a 0.05% increase in EPS estimates over the past 30 days, suggesting investor optimism about its future performance, which could positively influence its stock price.
- Valuation Analysis: With a forward P/E ratio of 17.14, Zoetis aligns with the industry average, while its PEG ratio of 1.84 indicates reasonable valuation in terms of expected earnings growth, reflecting its competitive position within the medical drugs industry.
See More
Zoetis (ZTS) Q2 2025 Earnings Call Transcript
See More
Zoetis (ZTS) Q1 2025 Earnings Call Transcript
See More
2026 S&P 500 Market Outlook
- Historical Indicator Confidence: Research from LPL Financial shows that since 1950, when the S&P 500 posts positive returns in January, it achieves positive returns for the full year 89% of the time, with an average gain of 16.7%, providing confidence for long-term investors despite a 7% drop at the start of 2026.
- Market Resilience Analysis: Data from Ryan Detrick indicates that despite numerous geopolitical shock events since 1940, the median market return of the S&P 500 12 months later was 7.4%, suggesting that the market has a strong recovery capability over the long term, encouraging investors to continue regular contributions.
- Investment Sentiment Factors: Investor optimism during uncertain times may drive market rebounds, and while short-term corrections of 10% and bear markets every three and a half years are common, long-term investing is still viewed as an effective strategy for beating inflation and building wealth.
- Recommended Investment Strategy: Despite current market turbulence, analysts suggest focusing on reasonably valued potential stocks, with the Motley Fool's analyst team identifying 10 best stocks expected to yield significant returns in the coming years, further emphasizing the importance of adhering to long-term investment principles in uncertain environments.
See More
Analysis of Investment Prospects in Healthcare Stocks
- Animal Health Leader: Zoetis has faced challenges over the past two years, including increased competition and scrutiny over drug side effects; however, its strong market position and the potential market for untreated dogs make it attractive for long-term investors, with expectations to continue launching new products to meet rising pet spending.
- New Drug Development Potential: BioNTech has underperformed in the coronavirus vaccine market, but its impressive pipeline with over 25 clinical trials in oncology, particularly the promising BNT327 developed with Bristol Myers Squibb, could set new standards of care across multiple indications, with significant clinical and regulatory progress expected over the next five years.
- Gene Editing Risks: Intellia Therapeutics' lonvo-z and nex-z are undergoing phase 3 studies but face uncertainty; despite the FDA lifting the hold on clinical trials, the high costs and complexities of gene editing treatments make steady revenue generation unlikely in the coming years, presenting substantial investment risks.
- Dividend Appeal: Zoetis has increased its dividends by 458% over the past decade, making it a top choice for income-seeking investors, reflecting its long-term investment value in the animal health market despite facing short-term challenges.
See More
Latest Rating Changes on Wall Street
- Apple's Positive Outlook: Wells Fargo reiterates Apple (AAPL) as overweight, anticipating better-than-expected iPhone demand and continued double-digit growth in services ahead of its earnings report, with a price target of $300.
- SolarEdge Downgraded: Goldman Sachs downgrades SolarEdge (SEDG) from neutral to sell, citing elevated expectations and challenging valuation as key factors behind the downgrade.
- Meta's Advertising Growth: Deutsche Bank maintains a buy rating on Meta (META), highlighting that its investments in AI are yielding increasing returns for advertisers, which supports accelerated advertising revenue growth.
- Autodesk Positioned Well: Jefferies initiates coverage on Autodesk (ADSK) with a buy rating, noting its strong positioning in agentic AI and solid fundamentals, presenting an attractive risk/reward profile at current levels.
See More
Zoetis Earnings Outlook Shows Optimism Ahead
- Stock Performance: Zoetis (ZTS) fell 1.78% to $117.86 in the latest trading session, underperforming the S&P 500's 0.11% decline, indicating market caution regarding its short-term outlook.
- Earnings Expectations: The company is set to report an EPS of $1.61 on May 7, 2026, representing an 8.78% increase year-over-year, with revenue projected at $2.31 billion, reflecting a 4.02% growth, showcasing its sustained growth potential in the animal health sector.
- Analyst Ratings: Currently holding a Zacks Rank of #3 (Hold), Zoetis has seen a 0.05% increase in EPS estimates over the past 30 days, suggesting investor optimism about its future performance, which could positively influence its stock price.
- Valuation Analysis: With a forward P/E ratio of 17.14, Zoetis aligns with the industry average, while its PEG ratio of 1.84 indicates reasonable valuation in terms of expected earnings growth, reflecting its competitive position within the medical drugs industry.
See More
Zoetis (ZTS) Q2 2025 Earnings Call Transcript
See More
Zoetis (ZTS) Q1 2025 Earnings Call Transcript
See More
2026 S&P 500 Market Outlook
- Historical Indicator Confidence: Research from LPL Financial shows that since 1950, when the S&P 500 posts positive returns in January, it achieves positive returns for the full year 89% of the time, with an average gain of 16.7%, providing confidence for long-term investors despite a 7% drop at the start of 2026.
- Market Resilience Analysis: Data from Ryan Detrick indicates that despite numerous geopolitical shock events since 1940, the median market return of the S&P 500 12 months later was 7.4%, suggesting that the market has a strong recovery capability over the long term, encouraging investors to continue regular contributions.
- Investment Sentiment Factors: Investor optimism during uncertain times may drive market rebounds, and while short-term corrections of 10% and bear markets every three and a half years are common, long-term investing is still viewed as an effective strategy for beating inflation and building wealth.
- Recommended Investment Strategy: Despite current market turbulence, analysts suggest focusing on reasonably valued potential stocks, with the Motley Fool's analyst team identifying 10 best stocks expected to yield significant returns in the coming years, further emphasizing the importance of adhering to long-term investment principles in uncertain environments.
See More
